Precision Optics Corporation reported a strong Q4 with record revenue of $8.8 million, a 42% increase year-over-year, surpassing analyst estimates of $7.1 million. The company also beat EPS expectations, posting -$0.01 versus the predicted -$0.06, signaling improved profitability. Gross margin rose significantly to 25.3% from 13.0% last year, and a current ratio of 2.28 indicates solid short-term financial health. Despite a negative trailing P/E ratio, the company's robust revenue growth and improved financial metrics suggest positive momentum going forward.
Precision Optics' Q4 report shows a record revenue of $8.8 million, a 42% increase year-over-year. For readers following the Health sector, here is Pluang's market snapshot as of Sep 29, 2026 22:11 WIB: out of 100 priced Health-sector US stocks tradable on Pluang, 17 rose and 82 fell today. Notable movers include ABCL at USD 14.28 with a 1-day change of +2.59% and Pluang order activity of 29% Sell / 71% Buy, NBIX at USD 136.83 with a 1-day change of -2.57% and balanced order activity, and NUWE at USD 0.74 with a 1-day change of -2.51% and 35% Sell / 65% Buy activity.
Analyst firm Craig-Hallum adjusted Boot Barn Holdings' price target to $224, an 84.91% increase from its recent stock price of $121.14, reflecting strong growth potential. The company aims to expand merchandise margins by 60 basis points in fiscal 20...
Inventiva announced improved financial results for the first half of 2026, reducing its net loss to €69.5 million from €175.9 million the previous year. The company completed the final patient visit in its Phase 3 NATiV3 trial for MASH, with topline ...
Jabil is set to report its Q4 earnings on September 30, 2026, with analysts expecting earnings per share around $4.07 and revenue near $9.71 billion, marking a 16.5% revenue increase year-over-year. The company is benefiting from robust growth in AI ...
Netflix shares rose 1.5% after Deutsche Bank upgraded the stock from Hold to Buy, citing recent price declines as a buying opportunity and stronger international trends. However, other analysts remain cautious, with Wells Fargo downgrading Netflix to...
Cytokinetics' CEO Robert I. Blum and other executives have recently sold large amounts of company stock, with Blum selling nearly 105,000 shares in total, including a major block under a pre-arranged trading plan. This insider selling occurs while th...
